The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity

**Background:** Research on employee care partners of patients with multiple sclerosis (MS) is limited. **Objectives:** The clinical and economic impact on employee care partners was evaluated by MS disease severity. **Methods:** Employees with spouses/domestic partners with MS from the Workpartners...

Full description

Bibliographic Details
Main Authors: Barry Hendin, Richard A. Brook, Ian A. Beren, Nathan Kleinman, Cindy Fink, Amy L. Phillips, Carroline Lobo
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2023-04-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/001c.57593
_version_ 1797341541933514752
author Barry Hendin
Richard A. Brook
Ian A. Beren
Nathan Kleinman
Cindy Fink
Amy L. Phillips
Carroline Lobo
author_facet Barry Hendin
Richard A. Brook
Ian A. Beren
Nathan Kleinman
Cindy Fink
Amy L. Phillips
Carroline Lobo
author_sort Barry Hendin
collection DOAJ
description **Background:** Research on employee care partners of patients with multiple sclerosis (MS) is limited. **Objectives:** The clinical and economic impact on employee care partners was evaluated by MS disease severity. **Methods:** Employees with spouses/domestic partners with MS from the Workpartners database (Jan. 1, 2010–Dec. 31, 2019) were eligible if: spouse/partner had at least 3 MS-related (ICD-9-CM/ICD-10-CM:340.xx/G35) inpatient/outpatient/disease-modifying therapy claims within 1 year (latest claim = index date); 6-month pre-index/1-year post-index enrollment; and age 18 to 64 years. Employee care partners’ demographic/clinical characteristics and direct/indirect costs were compared across predetermined MS severity categories. Logistic and generalized linear regression modeled the costs. **Results:** Among 1041 employee care partners of patients with MS, 358 (34.4%) patients had mild MS, 491 (47.2%) moderate, and 192 (18.4%) severe. Mean (standard error [SE]) employee care partner age was 49.0 (0.5) for patients with mild disease, 50.5 (0.4) for moderate, 51.7 (0.6) for severe; percent female care partners was 24.6% [2.3%] mild, 19.8% [1.8%] moderate, 27.6% [3.2%] severe; and mean care partner Charlson Comorbidity Index scores 0.28 (0.05) mild, 0.30 (0.04) moderate, 0.27 (0.06) severe. More care partners of patients with moderate/severe vs mild MS had hyperlipidemia (32.6%/31.8% vs 21.2%), hypertension (29.5%/29.7% vs 19.3%), gastrointestinal disease (20.8%/22.9% vs 13.1%), depression (9.2%/10.9% vs 3.9%), and anxiety 10.6%/8.9% vs 4.2%). Adjusted mean medical costs were greater for employee care partners of patients with moderate vs mild/severe disease (_P_<.001). Pharmacy costs (SE) were lower for employee care partners of mild vs severe/moderate patients (_P_<.005). Sick leave costs (SE) were greater for employee care partners of mild/severe vs moderate patients (_P_<.05). **Discussion:** Employee care partners of patients with moderate/severe vs mild MS had more comorbidities (ie, hypertension, gastrointestinal disease, depression, and anxiety) and higher pharmacy costs. Employee care partners of patients with moderate vs mild/severe MS had higher medical and lower sick leave costs. Treatment strategies that improve patient outcomes may reduce employee care partner burden and lower costs for employers in some instances. **Conclusions:** Comorbidities and direct/indirect costs of employees whose spouses/partners have MS were considerable and varied with MS severity.
first_indexed 2024-03-08T10:20:33Z
format Article
id doaj.art-56026b792be842d882d185ed142dd179
institution Directory Open Access Journal
issn 2327-2236
language English
last_indexed 2024-03-08T10:20:33Z
publishDate 2023-04-01
publisher Columbia Data Analytics, LLC
record_format Article
series Journal of Health Economics and Outcomes Research
spelling doaj.art-56026b792be842d882d185ed142dd1792024-01-28T00:05:20ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362023-04-01101The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease SeverityBarry HendinRichard A. BrookIan A. BerenNathan KleinmanCindy FinkAmy L. PhillipsCarroline Lobo**Background:** Research on employee care partners of patients with multiple sclerosis (MS) is limited. **Objectives:** The clinical and economic impact on employee care partners was evaluated by MS disease severity. **Methods:** Employees with spouses/domestic partners with MS from the Workpartners database (Jan. 1, 2010–Dec. 31, 2019) were eligible if: spouse/partner had at least 3 MS-related (ICD-9-CM/ICD-10-CM:340.xx/G35) inpatient/outpatient/disease-modifying therapy claims within 1 year (latest claim = index date); 6-month pre-index/1-year post-index enrollment; and age 18 to 64 years. Employee care partners’ demographic/clinical characteristics and direct/indirect costs were compared across predetermined MS severity categories. Logistic and generalized linear regression modeled the costs. **Results:** Among 1041 employee care partners of patients with MS, 358 (34.4%) patients had mild MS, 491 (47.2%) moderate, and 192 (18.4%) severe. Mean (standard error [SE]) employee care partner age was 49.0 (0.5) for patients with mild disease, 50.5 (0.4) for moderate, 51.7 (0.6) for severe; percent female care partners was 24.6% [2.3%] mild, 19.8% [1.8%] moderate, 27.6% [3.2%] severe; and mean care partner Charlson Comorbidity Index scores 0.28 (0.05) mild, 0.30 (0.04) moderate, 0.27 (0.06) severe. More care partners of patients with moderate/severe vs mild MS had hyperlipidemia (32.6%/31.8% vs 21.2%), hypertension (29.5%/29.7% vs 19.3%), gastrointestinal disease (20.8%/22.9% vs 13.1%), depression (9.2%/10.9% vs 3.9%), and anxiety 10.6%/8.9% vs 4.2%). Adjusted mean medical costs were greater for employee care partners of patients with moderate vs mild/severe disease (_P_<.001). Pharmacy costs (SE) were lower for employee care partners of mild vs severe/moderate patients (_P_<.005). Sick leave costs (SE) were greater for employee care partners of mild/severe vs moderate patients (_P_<.05). **Discussion:** Employee care partners of patients with moderate/severe vs mild MS had more comorbidities (ie, hypertension, gastrointestinal disease, depression, and anxiety) and higher pharmacy costs. Employee care partners of patients with moderate vs mild/severe MS had higher medical and lower sick leave costs. Treatment strategies that improve patient outcomes may reduce employee care partner burden and lower costs for employers in some instances. **Conclusions:** Comorbidities and direct/indirect costs of employees whose spouses/partners have MS were considerable and varied with MS severity.https://doi.org/10.36469/001c.57593
spellingShingle Barry Hendin
Richard A. Brook
Ian A. Beren
Nathan Kleinman
Cindy Fink
Amy L. Phillips
Carroline Lobo
The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity
Journal of Health Economics and Outcomes Research
title The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity
title_full The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity
title_fullStr The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity
title_full_unstemmed The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity
title_short The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity
title_sort clinical and economic impact of employees who are care partners of patients with multiple sclerosis by disease severity
url https://doi.org/10.36469/001c.57593
work_keys_str_mv AT barryhendin theclinicalandeconomicimpactofemployeeswhoarecarepartnersofpatientswithmultiplesclerosisbydiseaseseverity
AT richardabrook theclinicalandeconomicimpactofemployeeswhoarecarepartnersofpatientswithmultiplesclerosisbydiseaseseverity
AT ianaberen theclinicalandeconomicimpactofemployeeswhoarecarepartnersofpatientswithmultiplesclerosisbydiseaseseverity
AT nathankleinman theclinicalandeconomicimpactofemployeeswhoarecarepartnersofpatientswithmultiplesclerosisbydiseaseseverity
AT cindyfink theclinicalandeconomicimpactofemployeeswhoarecarepartnersofpatientswithmultiplesclerosisbydiseaseseverity
AT amylphillips theclinicalandeconomicimpactofemployeeswhoarecarepartnersofpatientswithmultiplesclerosisbydiseaseseverity
AT carrolinelobo theclinicalandeconomicimpactofemployeeswhoarecarepartnersofpatientswithmultiplesclerosisbydiseaseseverity
AT barryhendin clinicalandeconomicimpactofemployeeswhoarecarepartnersofpatientswithmultiplesclerosisbydiseaseseverity
AT richardabrook clinicalandeconomicimpactofemployeeswhoarecarepartnersofpatientswithmultiplesclerosisbydiseaseseverity
AT ianaberen clinicalandeconomicimpactofemployeeswhoarecarepartnersofpatientswithmultiplesclerosisbydiseaseseverity
AT nathankleinman clinicalandeconomicimpactofemployeeswhoarecarepartnersofpatientswithmultiplesclerosisbydiseaseseverity
AT cindyfink clinicalandeconomicimpactofemployeeswhoarecarepartnersofpatientswithmultiplesclerosisbydiseaseseverity
AT amylphillips clinicalandeconomicimpactofemployeeswhoarecarepartnersofpatientswithmultiplesclerosisbydiseaseseverity
AT carrolinelobo clinicalandeconomicimpactofemployeeswhoarecarepartnersofpatientswithmultiplesclerosisbydiseaseseverity